Target intelligence / Profile preview

Terminal D-alanyl-D-alanine motif of peptidoglycan precursors (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Peptidoglycan precursor, Bacterial cell wall component, Dipeptide motif
01

Overview

The terminal D-alanyl-D-alanine (D-Ala-D-Ala) motif is a critical structural component of the peptidoglycan precursors in the cell walls of Gram-positive bacteria. It serves as the substrate for transpeptidase enzymes, also known as penicillin-binding proteins, which catalyze the cross-linking of peptidoglycan chains to provide mechanical strength to the bacterial cell wall (StatPearls, 2023). This motif is the primary target for glycopeptide antibiotics, such as vancomycin and teicoplanin, which bind to the dipeptide via five hydrogen bonds (Nature Reviews Microbiology, 2017). By sequestering the D-Ala-D-Ala terminus, these drugs sterically hinder the enzymes responsible for cell wall polymerization and cross-linking, leading to bacterial cell lysis and death. Resistance to these antibiotics often involves the modification of this target, where the terminal D-alanine is replaced by D-lactate or D-serine, significantly reducing the binding affinity of the drug (Journal of Biological Chemistry, 2014). Understanding this motif is essential for the development of next-generation antibiotics designed to overcome bacterial resistance mechanisms.

Other names
D-alanyl-D-alanine terminusD-Ala-D-Ala dipeptidePeptidoglycan pentapeptide terminusD-Ala-D-Ala motif
02

Mechanism of action

Glycopeptide antibiotics bind to the D-alanyl-D-alanine terminus of peptidoglycan precursors through hydrogen bonding, sterically inhibiting the transglycosylation and transpeptidation steps required for cell wall assembly.

03

Biological functions

Cell wall synthesisPeptidoglycan cross-linkingBacterial structural integrity
04

Disease associations

Bacterial infection
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndrome (infusion reaction)Emergence of glycopeptide-resistant enterococci (VRE)Vancomycin-resistant Staphylococcus aureus (VRSA)
06

Interacting drugs

Vancomycin

4 more in the full profile.

07

Biomarkers

D-alanyl-D-lactate (D-Ala-D-Lac) substitutionD-alanyl-D-serine (D-Ala-D-Ser) substitutionVanA/VanB gene presence

Beyond the preview

Go deeper on Terminal D-alanyl-D-alanine motif of peptidoglycan precursors (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Terminal D-alanyl-D-alanine motif of peptidoglycan precursors (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call